Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan den Broeder

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Gastroenterology|May 21, 2020
Noninferiority or Nonsuperiority?Maarten Te Groen, Nathan den Broeder, Frank Hoentjen
Rheumatology Advances in Practice|March 11, 2021
(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challengesAlfons A den Broeder, Nathan den Broeder, Lise M Verhoef
Rheumatology International|January 29, 2024
Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort studyLisa Schapink, Nathan den Broeder, Alfons A den Broeder, et al.
Trials|April 16, 2022
PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trialDiane E Marsman, Thomas E Bolhuis, Nathan den Broeder, et al.
The Lancet. Rheumatology|January 22, 2024
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trialThomas E Bolhuis, Diane E Marsman, Alfons A den Broeder, et al.
Clinical and Experimental Rheumatology|February 26, 2021
Seasonal influence on incidence of polymyalgia rheumatica: winter might be comingDiane E Marsman, Nathan den Broeder, Calin D Popa, et al.
Trials|April 19, 2023
Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trialIris Rose Peeters, Alfons A den Broeder, William J Taylor, et al.
Rheumatology International|January 24, 2021
Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective studyDiane Marsman, Thomas Bolhuis, Nathan den Broeder, et al.
Clinical and Experimental Rheumatology|March 25, 2017
The effects of an educational meeting and subsequent computer reminders on the ordering of laboratory tests by rheumatologists: an interrupted time series analysisNienke Lesuis, Nathan den Broeder, Nadine Boers, et al.
European Journal of Gastroenterology & Hepatology|February 20, 2025
Characteristics, risk factors, and disease course of musculoskeletal manifestations in patients with inflammatory bowel disease: a prospective longitudinal cohort studyFenna M Jansen, Nathan den Broeder, Tamara W van Hal, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Gastroenterology|May 21, 2020
Noninferiority or Nonsuperiority?Maarten Te Groen, Nathan den Broeder, Frank Hoentjen
Rheumatology Advances in Practice|March 11, 2021
(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challengesAlfons A den Broeder, Nathan den Broeder, Lise M Verhoef
Rheumatology International|January 29, 2024
Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort studyLisa Schapink, Nathan den Broeder, Alfons A den Broeder, et al.
Trials|April 16, 2022
PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trialDiane E Marsman, Thomas E Bolhuis, Nathan den Broeder, et al.
The Lancet. Rheumatology|January 22, 2024
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trialThomas E Bolhuis, Diane E Marsman, Alfons A den Broeder, et al.
Clinical and Experimental Rheumatology|February 26, 2021
Seasonal influence on incidence of polymyalgia rheumatica: winter might be comingDiane E Marsman, Nathan den Broeder, Calin D Popa, et al.
Trials|April 19, 2023
Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trialIris Rose Peeters, Alfons A den Broeder, William J Taylor, et al.
Rheumatology International|January 24, 2021
Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective studyDiane Marsman, Thomas Bolhuis, Nathan den Broeder, et al.
Clinical and Experimental Rheumatology|March 25, 2017
The effects of an educational meeting and subsequent computer reminders on the ordering of laboratory tests by rheumatologists: an interrupted time series analysisNienke Lesuis, Nathan den Broeder, Nadine Boers, et al.
European Journal of Gastroenterology & Hepatology|February 20, 2025
Characteristics, risk factors, and disease course of musculoskeletal manifestations in patients with inflammatory bowel disease: a prospective longitudinal cohort studyFenna M Jansen, Nathan den Broeder, Tamara W van Hal, et al.
Pageof 6